vs

Side-by-side financial comparison of LIFETIME BRANDS, INC (LCUT) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.

LIFETIME BRANDS, INC is the larger business by last-quarter revenue ($204.1M vs $196.9M, roughly 1.0× Pacira BioSciences, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs -5.2%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $2.6M). Over the past eight quarters, LIFETIME BRANDS, INC's revenue compounded faster (19.8% CAGR vs 8.5%).

Yum! Brands, Inc. is an American multinational fast food corporation. It was formed in 1977 as a subsidiary of PepsiCo, after the company acquired KFC, Pizza Hut, and Taco Bell. PepsiCo divested the brands in 1997, and these consolidated as Yum!. The company operates KFC, Pizza Hut, Taco Bell, Habit Burger & Grill, and several technology companies.

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.

LCUT vs PCRX — Head-to-Head

Bigger by revenue
LCUT
LCUT
1.0× larger
LCUT
$204.1M
$196.9M
PCRX
Growing faster (revenue YoY)
PCRX
PCRX
+10.3% gap
PCRX
5.1%
-5.2%
LCUT
More free cash flow
PCRX
PCRX
$40.9M more FCF
PCRX
$43.5M
$2.6M
LCUT
Faster 2-yr revenue CAGR
LCUT
LCUT
Annualised
LCUT
19.8%
8.5%
PCRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LCUT
LCUT
PCRX
PCRX
Revenue
$204.1M
$196.9M
Net Profit
$18.2M
Gross Margin
38.6%
79.5%
Operating Margin
9.8%
1.2%
Net Margin
8.9%
Revenue YoY
-5.2%
5.1%
Net Profit YoY
103.5%
EPS (diluted)
$0.83
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LCUT
LCUT
PCRX
PCRX
Q4 25
$204.1M
$196.9M
Q3 25
$171.9M
$179.5M
Q2 25
$131.9M
$181.1M
Q1 25
$140.1M
$168.9M
Q4 24
$215.2M
$187.3M
Q3 24
$183.8M
$168.6M
Q2 24
$141.7M
$178.0M
Q1 24
$142.2M
$167.1M
Net Profit
LCUT
LCUT
PCRX
PCRX
Q4 25
$18.2M
Q3 25
$-1.2M
$5.4M
Q2 25
$-39.7M
$-4.8M
Q1 25
$-4.2M
$4.8M
Q4 24
$8.9M
Q3 24
$344.0K
$-143.5M
Q2 24
$-18.2M
$18.9M
Q1 24
$-6.3M
$9.0M
Gross Margin
LCUT
LCUT
PCRX
PCRX
Q4 25
38.6%
79.5%
Q3 25
35.1%
80.9%
Q2 25
38.6%
77.4%
Q1 25
36.1%
79.7%
Q4 24
37.7%
78.7%
Q3 24
36.7%
76.9%
Q2 24
38.5%
75.1%
Q1 24
40.5%
71.6%
Operating Margin
LCUT
LCUT
PCRX
PCRX
Q4 25
9.8%
1.2%
Q3 25
3.9%
3.5%
Q2 25
-28.2%
4.7%
Q1 25
0.8%
1.2%
Q4 24
7.2%
13.2%
Q3 24
4.7%
-82.8%
Q2 24
0.8%
15.9%
Q1 24
1.3%
7.9%
Net Margin
LCUT
LCUT
PCRX
PCRX
Q4 25
8.9%
Q3 25
-0.7%
3.0%
Q2 25
-30.1%
-2.7%
Q1 25
-3.0%
2.8%
Q4 24
4.1%
Q3 24
0.2%
-85.1%
Q2 24
-12.8%
10.6%
Q1 24
-4.4%
5.4%
EPS (diluted)
LCUT
LCUT
PCRX
PCRX
Q4 25
$0.83
$0.05
Q3 25
$-0.05
$0.12
Q2 25
$-1.83
$-0.11
Q1 25
$-0.19
$0.10
Q4 24
$0.41
$0.38
Q3 24
$0.02
$-3.11
Q2 24
$-0.85
$0.39
Q1 24
$-0.29
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LCUT
LCUT
PCRX
PCRX
Cash + ST InvestmentsLiquidity on hand
$4.3M
$238.4M
Total DebtLower is stronger
$135.0M
$372.2M
Stockholders' EquityBook value
$202.3M
$693.1M
Total Assets
$572.6M
$1.3B
Debt / EquityLower = less leverage
0.67×
0.54×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LCUT
LCUT
PCRX
PCRX
Q4 25
$4.3M
$238.4M
Q3 25
$12.1M
$246.3M
Q2 25
$12.0M
$445.9M
Q1 25
$10.4M
$493.6M
Q4 24
$2.9M
$484.6M
Q3 24
$6.0M
$453.8M
Q2 24
$3.4M
$404.2M
Q1 24
$4.6M
$325.9M
Total Debt
LCUT
LCUT
PCRX
PCRX
Q4 25
$135.0M
$372.2M
Q3 25
$376.7M
Q2 25
$580.5M
Q1 25
$583.4M
Q4 24
$142.5M
$585.3M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
LCUT
LCUT
PCRX
PCRX
Q4 25
$202.3M
$693.1M
Q3 25
$184.6M
$727.2M
Q2 25
$185.8M
$757.8M
Q1 25
$225.7M
$798.5M
Q4 24
$229.9M
$778.3M
Q3 24
$220.9M
$749.6M
Q2 24
$219.8M
$879.3M
Q1 24
$223.7M
$892.2M
Total Assets
LCUT
LCUT
PCRX
PCRX
Q4 25
$572.6M
$1.3B
Q3 25
$581.1M
$1.3B
Q2 25
$551.9M
$1.5B
Q1 25
$594.6M
$1.6B
Q4 24
$634.3M
$1.6B
Q3 24
$668.7M
$1.5B
Q2 24
$617.0M
$1.6B
Q1 24
$602.7M
$1.6B
Debt / Equity
LCUT
LCUT
PCRX
PCRX
Q4 25
0.67×
0.54×
Q3 25
0.52×
Q2 25
0.77×
Q1 25
0.73×
Q4 24
0.62×
0.75×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LCUT
LCUT
PCRX
PCRX
Operating Cash FlowLast quarter
$3.7M
$43.7M
Free Cash FlowOCF − Capex
$2.6M
$43.5M
FCF MarginFCF / Revenue
1.3%
22.1%
Capex IntensityCapex / Revenue
0.6%
0.1%
Cash ConversionOCF / Net Profit
0.21×
TTM Free Cash FlowTrailing 4 quarters
$3.3M
$136.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LCUT
LCUT
PCRX
PCRX
Q4 25
$3.7M
$43.7M
Q3 25
$-22.2M
$60.8M
Q2 25
$9.3M
$12.0M
Q1 25
$16.7M
$35.5M
Q4 24
$20.3M
$33.1M
Q3 24
$-22.7M
$53.9M
Q2 24
$10.4M
$53.2M
Q1 24
$10.5M
$49.1M
Free Cash Flow
LCUT
LCUT
PCRX
PCRX
Q4 25
$2.6M
$43.5M
Q3 25
$-22.7M
$57.0M
Q2 25
$8.2M
$9.3M
Q1 25
$15.1M
$26.9M
Q4 24
$19.7M
$31.0M
Q3 24
$-23.2M
$49.8M
Q2 24
$9.9M
$51.6M
Q1 24
$9.9M
$46.3M
FCF Margin
LCUT
LCUT
PCRX
PCRX
Q4 25
1.3%
22.1%
Q3 25
-13.2%
31.7%
Q2 25
6.2%
5.1%
Q1 25
10.8%
15.9%
Q4 24
9.1%
16.6%
Q3 24
-12.6%
29.6%
Q2 24
7.0%
29.0%
Q1 24
7.0%
27.7%
Capex Intensity
LCUT
LCUT
PCRX
PCRX
Q4 25
0.6%
0.1%
Q3 25
0.3%
2.2%
Q2 25
0.9%
1.5%
Q1 25
1.1%
5.1%
Q4 24
0.3%
1.1%
Q3 24
0.3%
2.4%
Q2 24
0.4%
0.9%
Q1 24
0.4%
1.7%
Cash Conversion
LCUT
LCUT
PCRX
PCRX
Q4 25
0.21×
Q3 25
11.20×
Q2 25
Q1 25
7.37×
Q4 24
2.28×
Q3 24
-65.89×
Q2 24
2.82×
Q1 24
5.47×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LCUT
LCUT

Kitchenware$114.3M56%
Tableware$41.7M20%
Home Solutions$29.4M14%
Other$18.8M9%

PCRX
PCRX

EXPAREL$155.8M79%
ZILRETTA$33.0M17%
Iovera$7.0M4%

Related Comparisons